Organisation: Novartis

In <i>PI Pharma v Novartis</i>, the Brussels Court of Appeal has expressed its views on the notification obligation of parallel importers of repackaged pharmaceuticals. It ruled that PI Pharma had not properly notified Novartis, the holder of the VENORUTON mark, when it provided a blister and a two-dimensional mock-up of the outer packaging, rather than an actual sample, of the repackaged pharmaceutical as it would be presented on sale.

04 March 2013

Over the past five years, the IP Business Congress has brought together senior industry professionals to discuss the latest issues around IP value creation. In December the IPBC will venture outside Europe and North America to take the discussion on how rights owners can strategically use intellectual property to create internal and external value to the Chinese market.

18 July 2012

Almost 1,500 nominations and two months of extensive research later, the shortlist for this year's WTR Industry Awards can now be revealed. The awards recognise the vital work of in-house trademark counsel and identify those teams and individuals that are performing their functions to the highest standards. The winners will be announced next month at an exclusive reception in Washington DC.

19 April 2012

In <i>Cadila Healthcare Ltd v OHIM</i>, the General Court has upheld a decision of the Second Board of Appeal of OHIM finding that there was a likelihood of confusion between the marks ZYDUS and ZIMBUS with regard to “pharmaceutical, veterinary and sanitary preparations”. Among other things, the court rejected the argument that the category of "pharmaceutical preparations" covers exclusively goods intended for the treatment of human beings.

30 March 2012